Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Kohli, Michele ^a   Lawrence, Donna ^a   Haig, Jennifer ^a   Anonychuk, Andrea ^b   Demarteau, Nadia ^b  

^a OPTUM   (United States)

^b GSK   (Belgium)

Author keywords

Canada; Cervical cancer; Cost effectiveness; Human papillomavirus; Markov model; Vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; WART VIRUS VACCINE;

ARTICLE; CANADA; CHILD; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; COST BENEFIT ANALYSIS; CROSS PROTECTION; ECONOMICS; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOLOGY; MASS IMMUNIZATION; METHODOLOGY; PAPILLOMAVIRUS INFECTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; STATISTICS; UTERINE CERVIX TUMOR; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; CANADA; CHILD; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; CROSS PROTECTION; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; MARKOV CHAINS; MASS VACCINATION; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS;

EID: 84867285149     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-872     Document Type: Article

References (89)

1. Canadian Immunization Committee, Recommendations on a Human papillomavirus vaccination program 2007 http://www5.statcan.gc.ca/cansim/a05?id= 1030550&pattern=&stByVal=3&paSer=&lang=eng.
2. Infection and cervical neoplasia: facts and fiction. Al-Daraji WI, Smith JH, Int J Clin Exp Pathol 2009 2 48 64 18830380
3. Global cancer statistics, 2002. Parkin DM, Bray F, Ferlay J, Pisani P, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078
4. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL, Vaccine 2006 24 26 S34
5. Epidemiologic classification of human papillomavirus types associated with cervical cancer. Muñoz N, Bosch FX, De Sanjose S, Herrero R, Castellsagué X, Shah KV, et al. N Engl J Med 2003 348 518 527 10.1056/NEJMoa021641 12571259
6. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Muñoz N, Bosch FX, Castellsagué X, Díaz M, De Sanjose S, Hammouda D, et al. Int J Cancer 2004 111 278 285 10.1002/ijc.20244 15197783
7. Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, De Sanjose S, Bruni L, et al. Vaccine 2008 26 1 K16 18847553
8. A review of human carcinogens-Part B: biological agents. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El GF, et al. Lancet Oncol 2009 10 321 322 10.1016/S1470-2045(09)70096-8 19350698
9. Insight on Cancer, News and Information on Cervical Cancer Toronto: Canadian Cancer Society (Ontario Division). Cancer Care Ontario 2005
10. Canadian Cancer Society/National Cancer Institute of Canada: Canadian cancer statistics 2010, Toronto, Canada 2010 http://www.cancer.ca/Canada-wide/ About%20cancer/Cancer%20statistics/media/CCS/Canada%20wide/Files%20List/ English%20files%20heading/pdf%20not%20in%20publications%20section/ Canadian20Cancer20Statistics2020102020English.ashx.
11. Immunization Schedule. HealthLinkBC, 2010 http://www.healthlinkbc.ca/ immunization.stm.
12. Parental intention to have daughters receive the human papillomavirus vaccine. Ogilvie GS, Remple VP, Marra F, McNeil SA, Naus M, Pielak KL, et al. Can Med Assoc J 2007 177 1506 1512 10.1503/cmaj.071022
13. Government of Alberta, Routine Immunization Schedule 2011 www.health.alberta.ca/health-info/imm-routine-schedule.html.
14. Saskatchewan, Immunization Schedule 2010 http://www.health.gov.sk.ca/ immunization-schedule.
15. Manitoba. Immunization Schedule, 2010 http://www.gov.mb.ca/health/ publichealth/cdc/schedule.html.
16. Publicly funded immunisation schedules for Ontario-January 2009, 2010 http://www.health.gov.on.ca/english/providers/program/immun/pdf/schedule.pdf.
17. Colucci R, Hryniuk W, Savage C, HPV Vaccination Programs in Canada: Are we hitting the mark? Report card on cancer in Canada 2008
18. Sante et services sociaux Quebec, HPV Vaccine Program 2010 http://www.msss.gouv.qc.ca/sujets/santepub/vaccination/index.php? programme-de-vaccination-contre-le-vph-en.
19. Sante et services sociaux Quebec. FlashVigie Bulletin quebecois de vigie et dintervention en maladie infectieuses, 2010 http://msssa4.msss.gouv.qc.ca/fr/ document/publication.nsf/4b1768b3f849519c852568fd0061480d/ 30bc6f2f39299a32852572720070cc98?OpenDocument5[3].
20. Newfoundland and Labrador. Immunization Schedule, 2010 http://www.health.gov.nl.ca/health/publichealth/cdc/immunizations-sched.html.
21. New Brunswick. Routine Immunization Schedule, 2010 http://www.gov.ns.ca/ hpp/publications/13153-CDPC-SchoolImmunizationSchedule.pdf.
22. Nova Scotia. Immunization Schedule, 2010 http://www.gov.ns.ca/hpp/ publications/13153-CDPC-SchoolImmunizationSchedule.pdf.
23. Prince Edward Island. Immunisation Schedule, 2010 http://www.gov.pe.ca/ health/index.php3?number=1021131&lang=E.
24. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Vaccine 2006 24 5937 5949 10.1016/j.vaccine.2006.06.005 16828940
25. Skinner R, Apter D, Chow SN WCDG for the HPV PATRICIA Study Group, Cross-protection efficacy of Cervarix against oncogenic HPV types beyond HPV-16/18: Final analysis of cross-protection- PATRICIA STUDY Malmö, Sweden: 25th International Papillomavirus Conference and Clinical Workshops 2009
26. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, et al. Lancet 2009 374 301 314 10.1016/S0140-6736(09)61248-4 19586656
27. The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Mauricio HA, Wheeler CM, et al. J Infect Dis 2009 199 926 935 10.1086/597307 19236279
28. Merck Canada Inc, GARDASIL® (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine) Health Canada: Product Monograph.Submission Control: 147972 2011 23151443
29. GlaxoSmithKline, Cervarix™ (Human papillomavirus (types 16, 18) recombinant adjuvanted, adsorbed vaccine) product monograph. Submission Control: 141721 Health Canada 8-16-2011. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/ databasdon/index-eng.php. 23162757
30. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. Anonychuk A, Bauch C, Merid MF, Van Kriekinge G, Demarteau N, BMC Publ Health 2009 9 401 10.1186/1471-2458-9-401
31. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. Rogoza RM, Ferko N, Bentley J, Meijer CJLM, Berkhof J, Wang KL, et al. Vaccine 2008 26 46 F58 18992382
32. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, et al. Vaccine 2008 26 16 F28 18992379
33. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Brisson M, van de Velde, De Wals P, Boily M-C, Vaccine 2007 25 5399 5408 10.1016/j.vaccine.2007.04.086 17561316
34. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Dee A, Howell F, Eur J Public Health 2010 20 213 219 10.1093/eurpub/ckp141 19864366
35. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia. Ezat SW, Aljunid S, Asian Pac J Cancer Prev 2010 11 943 951 21133606
36. Anti-HPV vaccination: a review of recent economic data for Italy. Mennini FS, Costa S, Favato G, Picardo M, Vaccine 2009 27 Suppl 1 54 A61 19480963
37. Economic evaluation of human papillomavirus vaccination in the United Kingdom. Jit M, Choi YH, Edmunds WJ, BMJ 2008 337 769 10.1136/bmj.a769 18640957
38. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination. Aljunid S, Zafar A, Saperi S, Amrizal M, Asian Pac J Cancer Prev 2010 11 1551 1559 21338196
39. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles. Capri S, Gasparini R, Panatto D, Demarteau N, Gynecol Oncol 2011 121 514 521 10.1016/j.ygyno.2011.01.029 21334734
40. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. Demarteau N, Standaert B, J Med Econ 2010 13 324 338 10.3111/13696998.2010.490481 20504110
41. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. Jit M, Chapman R, Hughes O, Choi YH, BMJ 2011 343 5775 10.1136/bmj.d5775 21951758
42. Budget impact analysis: review of the state of the art. Mauskopf JA, Earnshaw S, Mullins CD, Expert Rev Pharmacoecon Outcomes Res 2005 5 65 79 10.1586/14737167.5.1.65 19807561
43. Statistics Canada. CANSIM Table 103-0550. New cases for ICD-O-3 primary sites of cancer (based on the July 2011 CCR tabulation file), by age group and sex, Canada, provinces and terriitories, annual (194880 series), 2011 http://www5.statcan.gc.ca/cansim/a05?id=1030550&pattern=&stByVal= 3&paSer=&lang=eng.
44. Epidemiology and costs associated with genital warts in Canada. Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA, Sex Transm Infect 2009 85 111 115 18981170
45. WHO/ICO Information Centre of HPV and Cervical Cancer (HPV Information Centre), Human Papillomavirus and Related Cancer in Canada 2010 www.who.int/hpvcentre.
46. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Lancet 2007 369 2161 2170 10.1016/S0140-6736(07)60946-5 17602732
47. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Lancet 2006 367 1247 1255 10.1016/S0140-6736(06)68439-0 16631880
48. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Lancet 2004 364 1757 1765 10.1016/S0140-6736(04)17398-4 15541448
49. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen O-E, et al. Br J Cancer 2006 95 1459 1466 10.1038/sj.bjc.6603469 17117182
50. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. N Engl J Med 2007 356 1928 1943 10.1056/NEJMoa061760 17494926
51. Tjalma W, Paavonen J, Naud P, Wheeler CM, Chow SN, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naïve population Belgrade, Serbia: 16th International meeting of the European Society of Gynaecological Oncology (ESGO) 2009
52. Statistics Canada. Pap smear, by age group, women aged 18 to 69, Canada, provinces, territories, health regions and peer groups, 2003, 2003 http://www.statcan.gc.ca/pub/82-221-x/2005002/t/html/4063576-eng.htm.
53. Lesion precancereuses et cancers du col de luterus diagnostiques par le frottis cervical, Ile-de-France, enquete Crisap, 2002. Bergeron C, Cartier I, Guldner L, Lassalle M, Savignoni A, Asselain B, Bulletin epidemiologique hebdomadaire 2005 2 5 6
54. Krahn M, McLachlin M, Pham B, Rosen B, Sander B, Grootendorst P, et al. Liquid-based techniques for cervical cancer screening: a systematic review and cost-effectiveness analysis Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health 2008
55. Cost-effectiveness of vaccination against cervical cancer: A multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Suarez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, et al. Vaccine 2008 26 29 F45 18992380
56. Cardiff Research Consortium, Health outcomes data repository 2007 https://www.crc-limited.co.uk.
57. Insinga R, Glass A, Rush B, Health state transitions following an abnormal pap smear: implications for health utility assessment in cost-effectiveness analyses Vancouver, Canada: 22nd International Papillomavirus Conference & Clinical Workshops 2005
58. Myers ER, Green S, Lipkus I, Patient preferences for health states related to HPV infection: visual analog scale versus time trade-off elicitation Mexico City, Mexico: 21st International Papillomavirus Conference 2004
59. Institute Of Medicine, Financing vaccines in the 21st century: assuring access and availability Washington DC: The National Academies Press 2003
60. WHO/ICO Information Centre of HPV and Cervical Cancer (HPV Information Centre), Human Papillomavirus and Related Cancer in North America 2010 www.who.int/hpvcentre.
61. Human papillomavirus genotype distribution in external acuminata condylomata: A large French national study (EDiTH IV). Aubin F, Prétet JL, Jacquard AC, Saunier M, Carcopino X, Jaroud F, et al. Clin Infect Dis 2008 47 610 615 10.1086/590560 18637758
62. TM]. Keam SJ, Harper DM, Drugs 2008 68 359 372 10.2165/00003495-200868030-00007 18257611
63. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. J Infect Dis 2009 199 936 944 10.1086/597309 19236277
64. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. J Natl Cancer Inst 2010 102 325 339 10.1093/jnci/djp534 20139221
65. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Lancet Oncol 2012 13 100 110 10.1016/S1470-2045(11)70287-X 22075170
66. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Lancet Oncol 2012 13 89 99 10.1016/S1470-2045(11)70286-8 22075171
67. Effectiveness and cost comparison of two strategies for hepatitis B vaccination of schoolchildren. Guay M, ClouaÌtre A-M, Blackburn M, Baron G, De Wals P, Roy C, et al. Can J Public Health 2003 94 64 67 12583682
68. World Health Organization, Preparing for the introduction of HPV vaccines: Policy and programme guidance for countries Geneva: World Health Organization Press 2006
69. World Health Organization, Report of the consultation on human papillomavirus vaccines Geneva: World Health Organization Press 2005
70. Impact of HPV vaccination on young womens quality of life-a five year follow-up study. Woodhall S, Eriksson T, Nykanen AM, Huhtala H, Rissanen P, Apter D, et al. Eur J Contracept Reprod Health Care 2011 16 3 8 10.3109/13625187.2010.536921 21158521
71. The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Drolet M, Brisson M, Maunsell E, Franco EL, Coutlee F, Ferenczy A, et al. Sex Transm Dis 2011 38 949 956 10.1097/OLQ. 0b013e3182215512 21934571
72. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. Brisson M, van d V, Franco EL, Drolet M, Boily MC, J Infect Dis 2011 204 372 376 10.1093/infdis/jir285 21742835
73. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Lancet Infect Dis 2011 11 39 44 10.1016/S1473-3099(10)70225-5 21067976
74. Incidence of Genital Warts in Sweden Before and After Quadrivalent Human Papillomavirus Vaccine Availability. Leval A, Herweijer E, Arnheim-Dahlstrom L, Walum H, Frans E, Sparen P, et al. J Infect Dis 2012
75. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. JAMA 2001 285 2995 3002 10.1001/jama.285.23.2995 11410098
76. Cost effectiveness of a potential vaccine for human papillomavirus. Sanders GD, Taira AV, Emerg Infect Dis 2003 9 37 48 10.3201/eid0901.020168 12533280
77. Modeling human papillomavirus vaccine effectiveness: Quantifying the impact of parameter uncertainty. Van de Velde N, Brisson M, Boily M-C, Am J Epidemiol 2007 165 762 775 10.1093/aje/kwk059 17276976
78. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Nobbenhuis MA, Meijer CJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Risse EK, et al. Br J Cancer 2001 84 796 801 10.1054/bjoc.2000.1689 11259094
79. Incidence, clearance and predictors of human papillomavirus infection in women. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, et al. Can Med Assoc J 2003 168 421 425
80. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Monsonego J, Breugelmans JG, Bouee S, Lafuma A, Benard S, Remy V, Gynecol Obstet Fertil 2007 35 107 113 10.1016/j.gyobfe.2006.12.010 17270482
81. Meta-analysis of Pap test accuracy. Fahey MT, Irwig L, Macaskill P, Am J Epidemiol 1995 141 680 689 7702044
82. Toward Consistency in Cost-Utility Analyses Using National Measures to Create Condition-Specific Values. Gold MR, Franks P, McCoy KI, Fryback DG, Med Care 1998 36 778 792 10.1097/00005650-199806000-00002 9630120
83. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. Villa LL, Perez G, Kjaer SK, Paavonen J, Lehtinen M, Muñoz N, et al. N Engl J Med 2007 356 1915 1927 17494925
84. WHO/ICO Information Centre of HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancer, 2010 www.who.int/hpvcentre.
85. Statistics Canada, Table 051-0001. Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual, CANSIM (database) 2010 22224255
86. Genital warts and cost of care in England. Desai S, Wetten S, Woodhall SC, Peters L, Hughes G, Soldan K, Sex Transm Infect 2011 87 464 468 10.1136/sti.2010.048421 21813567
87. World Health Organization guide for the standardization of immunisation programmes: final version, Geneva Switzerland: World Health Organization 2008
88. ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Hum Vaccin 2009 5 705 719 10.4161/hv.5.10.9518 19684472
89. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from Months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, et al. Hum Vaccin 2011 7 1343 1358 10.4161/hv.7.12.18281 22048173